Long-term dynamic-choice program to reduce HIV treatment interruptions in Malawi

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional project enrolls ART clients in Malawi who are more than 28 days late for their last appointment and are at least 15 years old and not pregnant. Participants will be offered a long-term, dynamic choice package that repackages existing clinic services and lets clients change which services they receive over time based on their needs. Study staff will provide ongoing follow-up and support during re-initiation and beyond to track retention, viral suppression, and repeat treatment interruption. The approach builds on prior short-term counseling and home-based ART interventions but extends choice and duration to try to prevent repeat interruptions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 15 years of age or older
* living with HIV;
* initiated ART for the first time\>3-months ago (i.e., not a new initiate);
* non-pregnant;
* experienced Treatment Interuptions during their most recent ARTappointment (\>28 days late).

Exclusion Criteria:

* pregnant women because the ART/antenatal care (ANC) programs are integrated and require additional considerations and linkages with antenatal services.

Where it's running

• Partners in Hope
  Lilongwe, Malawi Recruiting

Study contacts

• Principal investigator: Kathryn L Dovel, PhD — University of California, Los Angeles
• Study coordinator: Kathryn L Dovel, PhD
• Email: kdovel@mednet.ucla.edu
• Phone: 310-267-5844

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Project SHIELD 2.0: Police Education to Support Public Health in Kentucky

  Aimed at police in Kentucky, this program tests whether SHIELD training given to officers, with health workers helping deliver it, can reduce drug-related arrests and steer people who use drugs toward MOUD and other health services.

  Recruiting Johns Hopkins Bloomberg School of Public Health · Lexington, Kentucky · NCT07804121

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• Bridge to Belonging: A Peer‑Led Program to Reduce Loneliness and Depression in older gay and bisexual men with HIV

  This program tests a peer-delivered, manualized approach to help men aged 50+ with HIV connect to LGBTQ+-affirming elder services to see if it reduces loneliness and depressive symptoms.

  Recruiting Fenway Community Health · Boston, Massachusetts · NCT07762066

• HIV vaccine test in healthy adults using CH505 nanoparticles and mRNA boosters

  This early-stage study will test the safety and immune responses of CH505 vaccine regimens in healthy adults to see if they can trigger HIV-specific immune protection.

  Recruiting at 2 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 7 other locations · NCT07757802

• Stigma-reducing program to help women who use drugs stay in HIV care

  This test checks whether a stigma-reduction program helps women living with HIV who use drugs stay engaged in HIV care in Ukraine.

  Recruiting Johns Hopkins Bloomberg School of Public Health · Kyiv, Kyiv Oblast · NCT07751978

• Platelets and HIV Reservoirs: A look at how platelets might harbor HIV in people living with HIV

  This observational study tests whether HIV can be found inside platelets in adults with suppressed HIV on therapy.

  Recruiting Tourcoing Hospital · Tourcoing · NCT07745530

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.